# A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct06907615/  
OnCo record `nct06907615` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HLX43 DOSE 1 (2.0 mg/kg) in non-small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.

## Summary

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06907615 by Shanghai Henlius Biotech, with 243 participants planned, started 2025-06-09 and due to reach its primary completion in 2028-04-20. Interventions recorded: HLX43 DOSE 1 (2.0 mg/kg) and HLX43 DOSE 2 (2.5 mg/kg).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06907615
- Phase: 2
- Setting: An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 243

## Sources

- ClinicalTrials.gov NCT06907615: https://clinicaltrials.gov/study/NCT06907615

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct06907615.json